Number of Participants Reporting Adverse Events 4-6 weeks after the first visit [clinicaltrials_resource:e72490007ac9bd7a596cf6a6d9b9399d]
Safety and tolerability of LDL lowering with co-administration therapy as measured by the number of participants reporting adverse events (AE). (AE defined as any untoward medical occurrence or unfavorable and unintended sign in a subject administered the pharmaceutical product whether or not considered related to the use of that product.)
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Number of Participants Reporting Adverse Events 4-6 weeks after the first visit [clinicaltrials_resource:e72490007ac9bd7a596cf6a6d9b9399d]
Safety and tolerability of LDL lowering with co-administration therapy as measured by the number of participants reporting adverse events (AE). (AE defined as any untoward medical occurrence or unfavorable and unintended sign in a subject administered the pharmaceutical product whether or not considered related to the use of that product.)
Bio2RDF identifier
e72490007ac9bd7a596cf6a6d9b9399d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e72490007ac9bd7a596cf6a6d9b9399d
measure [clinicaltrials_vocabulary:measure]
Number of Participants Reporting Adverse Events
time frame [clinicaltrials_vocabulary:time-frame]
4-6 weeks after the first visit
description
Safety and tolerability of LDL ...... d to the use of that product.)
identifier
clinicaltrials_resource:e72490007ac9bd7a596cf6a6d9b9399d
title
Number of Participants Reporting Adverse Events 4-6 weeks after the first visit
@en
type
label
Number of Participants Reporti ...... 490007ac9bd7a596cf6a6d9b9399d]
@en